BioAge Labs (NASDAQ:BIOA) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of BioAge Labs (NASDAQ:BIOA) from a sell rating to a hold rating in a report issued on Sunday.

Several other equities analysts have also recently commented on BIOA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAge Labs in a research report on Thursday, October 30th. Citigroup increased their target price on BioAge Labs from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, BioAge Labs currently has a consensus rating of “Hold” and an average target price of $15.00.

BioAge Labs Trading Down 6.3%

Shares of BIOA stock opened at $20.16 on Friday. The company has a market cap of $722.74 million, a PE ratio of -13.26 and a beta of 1.38. The company’s fifty day simple moving average is $12.22 and its 200-day simple moving average is $7.69. BioAge Labs has a 52 week low of $2.88 and a 52 week high of $24.00.

BioAge Labs (NASDAQ:BIOA) last posted its earnings results on Thursday, November 6th. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.11. The firm had revenue of $2.05 million for the quarter.

Insider Activity at BioAge Labs

In related news, CFO Dov A. Md Goldstein sold 27,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $19.70, for a total transaction of $531,900.00. Following the sale, the chief financial officer owned 22,408 shares of the company’s stock, valued at $441,437.60. The trade was a 54.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Paul D. Rubin sold 68,897 shares of BioAge Labs stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $10.19, for a total value of $702,060.43. The disclosure for this sale is available in the SEC filing. Insiders sold 347,004 shares of company stock worth $5,673,859 in the last 90 days. Corporate insiders own 20.82% of the company’s stock.

Institutional Trading of BioAge Labs

Several institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE increased its holdings in BioAge Labs by 46.3% in the third quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock worth $65,000 after buying an additional 3,517 shares during the last quarter. Vontobel Holding Ltd. increased its stake in shares of BioAge Labs by 36.4% during the 3rd quarter. Vontobel Holding Ltd. now owns 15,000 shares of the company’s stock worth $88,000 after purchasing an additional 4,000 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of BioAge Labs in the 3rd quarter valued at $27,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in BioAge Labs by 85.6% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock worth $54,000 after buying an additional 5,976 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey bought a new position in BioAge Labs during the second quarter valued at about $27,000.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.